Cargando…
Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection
Monoclonal antibody therapies for COVID-19 have been frequently used in adults, whereas there are little data regarding the safety or efficacy of monoclonal antibody treatments in pediatric patients affected by COVID-19. We report our experience in the administration of mAb as a treatment for SARS-C...
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947030/ https://www.ncbi.nlm.nih.gov/pubmed/35327741 http://dx.doi.org/10.3390/children9030369 |
| _version_ | 1784674341656461312 |
|---|---|
| author | Romani, Lorenza Calò Carducci, Francesca Ippolita Chiurchiù, Sara Cursi, Laura De Luca, Maia Di Giuseppe, Martina Krzysztofiak, Andrzej Lancella, Laura Palma, Paolo Vallesi, Leonardo Corsetti, Tiziana Campana, Andrea Nicastri, Emanuele Rossi, Paolo Bernardi, Stefania |
| author_facet | Romani, Lorenza Calò Carducci, Francesca Ippolita Chiurchiù, Sara Cursi, Laura De Luca, Maia Di Giuseppe, Martina Krzysztofiak, Andrzej Lancella, Laura Palma, Paolo Vallesi, Leonardo Corsetti, Tiziana Campana, Andrea Nicastri, Emanuele Rossi, Paolo Bernardi, Stefania |
| author_sort | Romani, Lorenza |
| collection | PubMed |
| description | Monoclonal antibody therapies for COVID-19 have been frequently used in adults, whereas there are little data regarding the safety or efficacy of monoclonal antibody treatments in pediatric patients affected by COVID-19. We report our experience in the administration of mAb as a treatment for SARS-CoV-2 infection in children aged from 24 days to 18 years old. |
| format | Online Article Text |
| id | pubmed-8947030 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | MDPI |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89470302022-03-25 Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection Romani, Lorenza Calò Carducci, Francesca Ippolita Chiurchiù, Sara Cursi, Laura De Luca, Maia Di Giuseppe, Martina Krzysztofiak, Andrzej Lancella, Laura Palma, Paolo Vallesi, Leonardo Corsetti, Tiziana Campana, Andrea Nicastri, Emanuele Rossi, Paolo Bernardi, Stefania Children (Basel) Communication Monoclonal antibody therapies for COVID-19 have been frequently used in adults, whereas there are little data regarding the safety or efficacy of monoclonal antibody treatments in pediatric patients affected by COVID-19. We report our experience in the administration of mAb as a treatment for SARS-CoV-2 infection in children aged from 24 days to 18 years old. MDPI 2022-03-07 /pmc/articles/PMC8947030/ /pubmed/35327741 http://dx.doi.org/10.3390/children9030369 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Communication Romani, Lorenza Calò Carducci, Francesca Ippolita Chiurchiù, Sara Cursi, Laura De Luca, Maia Di Giuseppe, Martina Krzysztofiak, Andrzej Lancella, Laura Palma, Paolo Vallesi, Leonardo Corsetti, Tiziana Campana, Andrea Nicastri, Emanuele Rossi, Paolo Bernardi, Stefania Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection |
| title | Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection |
| title_full | Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection |
| title_fullStr | Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection |
| title_full_unstemmed | Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection |
| title_short | Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection |
| title_sort | safety of monoclonal antibodies in children affected by sars-cov-2 infection |
| topic | Communication |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947030/ https://www.ncbi.nlm.nih.gov/pubmed/35327741 http://dx.doi.org/10.3390/children9030369 |
| work_keys_str_mv | AT romanilorenza safetyofmonoclonalantibodiesinchildrenaffectedbysarscov2infection AT calocarduccifrancescaippolita safetyofmonoclonalantibodiesinchildrenaffectedbysarscov2infection AT chiurchiusara safetyofmonoclonalantibodiesinchildrenaffectedbysarscov2infection AT cursilaura safetyofmonoclonalantibodiesinchildrenaffectedbysarscov2infection AT delucamaia safetyofmonoclonalantibodiesinchildrenaffectedbysarscov2infection AT digiuseppemartina safetyofmonoclonalantibodiesinchildrenaffectedbysarscov2infection AT krzysztofiakandrzej safetyofmonoclonalantibodiesinchildrenaffectedbysarscov2infection AT lancellalaura safetyofmonoclonalantibodiesinchildrenaffectedbysarscov2infection AT palmapaolo safetyofmonoclonalantibodiesinchildrenaffectedbysarscov2infection AT vallesileonardo safetyofmonoclonalantibodiesinchildrenaffectedbysarscov2infection AT corsettitiziana safetyofmonoclonalantibodiesinchildrenaffectedbysarscov2infection AT campanaandrea safetyofmonoclonalantibodiesinchildrenaffectedbysarscov2infection AT nicastriemanuele safetyofmonoclonalantibodiesinchildrenaffectedbysarscov2infection AT rossipaolo safetyofmonoclonalantibodiesinchildrenaffectedbysarscov2infection AT bernardistefania safetyofmonoclonalantibodiesinchildrenaffectedbysarscov2infection |